Clinical Study on the Application of a Non-Invasive Micro-Focused Ultrasound With Visualization System for Skin Laxity (ULT-215)

Not Applicable

Completed

• Conditions: Facial Skin Laxity
• Interventions: Device: Microfocused ultrasound with visualization

• Registration Number: NCT03545412
• Lead Sponsor: Ulthera, Inc

Brief Summary

To evaluate the effect of the Ulthera® system for facial laxity and sagging skin

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01-10
• Primary Completion: 2014-05-20
• Study Completion: 2014-08-20
• Status Verified: 2018-05
• Study First Submitted: 2018-05-22
• Study First Submitted QC: 2018-05-22
• Study First Posted: 2018-06-04
• Results First Submitted: 2018-11-20
• Results First Submitted QC: 2018-11-20
• Last Update Submitted: 2018-11-20
• Results First Posted: 2018-12-12
• Last Update Posted: 2018-12-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

1. Willing to sign a written consent form
2. Willing to have of facial skin laxity and wrinkles assessed by clinician
3. Male or female, aged 39 to 65 years.
4. Willingness to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
5. Willingness to cooperate with photography and adherence to photography procedures (i.e., removal of jewelry and makeup).
6. Must understand the ultrasound device (Ulthera) treatment may have no therapeutic effect.
7. Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure.

Exclusion Criteria

1. Open wounds or lesions in the area(s) to be treated.
2. Severe or cystic acne on the area(s) to be treated.
3. Presence of an active systemic or local skin disease that may affect wound healing.
4. Active implants (e.g., pacemakers or defibrillators), or metallic implants in the treatment areas (dental implants not included.).
5. Subcutaneous fillers
6. Keloid scar
7. Patients with anticoagulant treatment plan.
8. Children, pregnant women, breastfeeding women.
9. Patients with the following disease conditions: bleeding disorders or coagulation disorder that may affect wound healing, active localized disease, herpes simplex, autoimmune diseases, diabetes, epilepsy bell-type paralysis (temporary facial palsy)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Microfocused ultrasound with visualization	Microfocused ultrasound with visualization	-

Primary Outcome Measures

Name	Time	Method
Number of Participants With Lift in Brow Region at Day 90	Baseline, Day 90	Lift improvement as measured by quantitative analysis was considered minimum 0.5 millimeter (mm) Day 90 photograph compared to baseline photograph. The quantitative analysis was calculated by using five evenly spaced points along the natural outline of each participant's brow. Brow height was calculated using the sum and average of the five calculations in each brow area.
Number of Participants With Improvement in Skin Laxity in Submental Region and Neck at Day 90	Baseline, Day 90	Lift improvement as measured by quantitative analysis was considered greater than or equal to (\>=) 20.0 square millimeter (mm\^2) of the submental area Day 90 photograph compared to baseline photograph. The quantitative analysis was calculated by using five evenly spaced points on the neck. Area was calculated in between each of the 5 points and then sum of the five calculations was the total area of the region of interest.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Improvement in Patient Satisfaction Questionnaire at Day 90	Day 90	Participants completed a PSQ at the 90-day visit. The PSQ has 5 satisfaction categories ranging from 'very dissatisfied' to 'very satisfied'.
Number of Participants With Overall Aesthetic Improvement as Assessed by the Physician Global Aesthetic Improvement Scale (PGAIS) at Day 180	Baseline, Day 180	Overall aesthetic improvement was assessed by the principal investigator using the GAIS. At 180 days post-treatment, each principal investigator completed a GAIS, known as PGAIS .The GAIS is 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Only participants who had any improvement were reported.
Number of Participants With Overall Aesthetic Improvement as Assessed by the Principal Investigator Using the Global Aesthetic Improvement Scale (PGAIS) at Day 90	Baseline, Day 90	Overall aesthetic improvement was assessed by the principal investigator using global aesthetic improvement scale (GAIS). At 90 days post-treatment, each principal investigator completed a GAIS, known as physician global aesthetic improvement scale (PGAIS) .The GAIS is 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Only participants who had any improvement were reported.
Number of Participants With Overall Aesthetic Improvement as Assessed by the Subject Global Aesthetic Improvement Scale (SGAIS) at Day 90	Baseline, Day 90	Overall aesthetic improvement was assessed by participants using global aesthetic improvement scale (GAIS). At 90 days post-treatment, each participant completed a GAIS, known as SGAIS.The GAIS is 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Only participants who had any improvement were reported.
Number of Participants With Overall Aesthetic Improvement as Assessed by the SGAIS at Day 180	Baseline, Day 180	Overall aesthetic improvement was assessed by participants using GAIS. At 180 days post-treatment, each participant completed a GAIS, known as SGAIS. The GAIS is 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Only participants who had any improvement were reported.